111 related articles for article (PubMed ID: 19373652)
1. Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Ocheni S; Iwanski GB; Schafhausen P; Zander AR; Ayuk F; Klyuchnikov E; Zabelina T; Fiedler W; Schnittger S; Hochhaus A; Brümmendorf TH; Kröger N; Bacher U
Leuk Lymphoma; 2009 Apr; 50(4):551-8. PubMed ID: 19373652
[TBL] [Abstract][Full Text] [Related]
2. Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia.
Zhao Y; Luo Y; Shi J; Cai Z; Huang H
Am J Med Sci; 2014 Jun; 347(6):439-45. PubMed ID: 24553398
[TBL] [Abstract][Full Text] [Related]
3. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
Strati P; Kantarjian H; Thomas D; O'Brien S; Konoplev S; Jorgensen JL; Luthra R; Abruzzo L; Jabbour E; Quintas-Cardama A; Borthakur G; Faderl S; Ravandi F; Cortes J
Cancer; 2014 Feb; 120(3):373-80. PubMed ID: 24151050
[TBL] [Abstract][Full Text] [Related]
4. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G
Leuk Res; 2010 Feb; 34(2):143-7. PubMed ID: 19481800
[TBL] [Abstract][Full Text] [Related]
5. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Kantarjian HM; O'Brien S; Cortes JE; Giralt SA; Rios MB; Shan J; Giles FJ; Thomas DA; Faderl S; De Lima M; Garcia-Manero G; Champlin R; Arlinghaus R; Talpaz M
Blood; 2002 Sep; 100(5):1590-5. PubMed ID: 12176876
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Saussele S; Lauseker M; Gratwohl A; Beelen DW; Bunjes D; Schwerdtfeger R; Kolb HJ; Ho AD; Falge C; Holler E; Schlimok G; Zander AR; Arnold R; Kanz L; Dengler R; Haferlach C; Schlegelberger B; Pfirrmann M; Müller MC; Schnittger S; Leitner A; Pletsch N; Hochhaus A; Hasford J; Hehlmann R;
Blood; 2010 Mar; 115(10):1880-5. PubMed ID: 19965667
[TBL] [Abstract][Full Text] [Related]
8. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation.
Koc Y; Miller KB; Schenkein DP; Daoust P; Sprague K; Berkman E
Cancer; 1999 Feb; 85(3):608-15. PubMed ID: 10091734
[TBL] [Abstract][Full Text] [Related]
9. Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT).
Cummins M; Cwynarski K; Marktel S; Dazzi F; Cavenagh J; Clark RE; Holyoake TL; Milligan D; Parker A; Russell NH; Marks DI;
Bone Marrow Transplant; 2005 Dec; 36(12):1065-9. PubMed ID: 16247434
[TBL] [Abstract][Full Text] [Related]
10. Extramedullary relapse of chronic myeloid leukemia in blast crisis: more questions than answers.
Ross DM
Leuk Lymphoma; 2009 Apr; 50(4):517-8. PubMed ID: 19373644
[No Abstract] [Full Text] [Related]
11. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
12. Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
Luo Y; Zhao Y; Tan Y; Shi J; Han X; Zheng Y; Li L; He J; Xie W; Ye X; Cai Z; Lin M; Huang H
Leuk Res; 2011 Oct; 35(10):1307-11. PubMed ID: 21354617
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
Weisser M; Schleuning M; Haferlach C; Schwerdtfeger R; Kolb HJ
Leuk Lymphoma; 2007 Feb; 48(2):295-301. PubMed ID: 17325889
[TBL] [Abstract][Full Text] [Related]
14. Granulocytic sarcoma of the stomach: relapse after hematopoietic stem-cell transplantation for chronic myeloid leukemia.
Macedo AV; Freitas IF; Oliveira FB; Resende C; Mendes CU; Vieira AK; Castro LC; Rego EM; Clementino NC; Bittencourt H
Hematol Oncol Stem Cell Ther; 2010; 3(2):94-8. PubMed ID: 20543544
[TBL] [Abstract][Full Text] [Related]
15. [Sustained remission with allogeneic peripheral blood stem cell transplantation and subsequent maintenance therapy with dasatinib in a patient with myeloblastic crisis of imatinib-resistant CML].
Narita T; Kayukawa S; Yoshida T; Kusumoto S; Kataoka T
Rinsho Ketsueki; 2013 Mar; 54(3):279-83. PubMed ID: 23676643
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
Rytting ME; Wierda WG
Leuk Lymphoma; 2004 Aug; 45(8):1623-6. PubMed ID: 15370215
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
Khoury HJ; Kukreja M; Goldman JM; Wang T; Halter J; Arora M; Gupta V; Rizzieri DA; George B; Keating A; Gale RP; Marks DI; McCarthy PL; Woolfrey A; Szer J; Giralt SA; Maziarz RT; Cortes J; Horowitz MM; Lee SJ
Bone Marrow Transplant; 2012 Jun; 47(6):810-6. PubMed ID: 21986636
[TBL] [Abstract][Full Text] [Related]
18. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
19. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Deau B; Nicolini FE; Guilhot J; Huguet F; Guerci A; Legros L; Pautas C; Berthou C; Guyotat D; Cony-Makhoul P; Gardembas M; Michallet M; Hayette S; Cayuela JM; Weiss IR; Réa D; Castaigne S; Mahon FX; Guilhot F; Rousselot P
Leuk Res; 2011 Jun; 35(6):777-82. PubMed ID: 21145590
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Giles F; Thomas D; Wierda W; Cortes J
Leuk Lymphoma; 2007 Feb; 48(2):283-9. PubMed ID: 17325887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]